Skip to content
DataLookout
Menu

NCT07900867

This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study description shortened, about 11 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 24
Timeframe: Baseline to Week 24

Secondary (6)

CLASI-70
CLASI-50
CLASI ≥7
CLA-IGA-R erythema
CLA-IGA-R OMC
Show 1 moreShow less
SLEDAI-2K

Arms and interventions

Group AExperimental

626 Dose A subcutaneous (SC) injection

Group BExperimental

626 Dose B subcutaneous (SC) injection

Group CExperimental

626 Dose C subcutaneous (SC) injection

Drugs: Placebo

Sites

2 sites in 1 country